Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard® Nerve Protector, Axoguard® Nerve Cap, Avive® Soft Tissue Membrane, Acroval® Neurosensory and Motor Testing System, Axotouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:
March 31,
December 31,
Finished goods $ 9,309  $ 8,876 
Work in process 782  751 
Raw materials 3,297  2,902 
Inventories $ 13,388  $ 12,529 
The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes-down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage.  For the three months ended March 31, 2021 and 2020, the Company had adjustments to the provision for inventory write downs of $783 and $924 respectively.